Sat.May 25, 2024 - Fri.May 31, 2024

article thumbnail

How to Get Into Medical Device Sales: Ultimate Career Guide

David Bagga

How to Get Into Medical Device Sales: Ultimate Career Guide Home Blog How to Get Into Medical Device Sales: Ultimate Career Guide How to Get Into Medical Device Sales: Ultimate Career Guide If you are new to medical device sales and interested in getting a job in this field, here are some essential tips that […] The post How to Get Into Medical Device Sales: Ultimate Career Guide appeared first on.

Medical 130
article thumbnail

Takeda, amid restructuring campaign, plots 641 layoffs at two Massachusetts sites

Fierce Pharma

A recently announced $900 million restructuring drive is already making waves at Takeda, wi | From early July to March 2025, the Japanese drugmaker will cut 495 staffers at its Cambridge location and 146 in Lexington, Massachusetts. Takeda is the largest life sciences employer in the state.

343
343
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mental Health Inequities Could Cost $1.3 Trillion in 2040. How Can the Industry Prevent This?

MedCity News

Mental health inequities are costing the U.S. $477.5 billion annually. This could rise to $1.3 trillion in 2040 if left unaddressed. The post Mental Health Inequities Could Cost $1.3 Trillion in 2040. How Can the Industry Prevent This? appeared first on MedCity News.

Medical 128
article thumbnail

COVID-19 vaccinations now ‘alarmingly low’ in Europe

pharmaphorum

COVID-19 vaccination rates have fallen precipitously in Europe and should be ramped up this autumn so they are at least in line with influenza vaccine uptake.

134
134
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

How to Get Medical Device Sales Jobs with No Experience?

David Bagga

How to Get Medical Device Sales Jobs with No Experience? Home Blog How to Get Medical Device Sales Jobs with No Experience? How to Get Medical Device Sales Jobs with No Experience? Medical device sales become one of the best career options today. More and more people want to crack medical device sales jobs and […] The post How to Get Medical Device Sales Jobs with No Experience?

Medical 130
article thumbnail

BioNTech, flush with $145M from CEPI, looks to expand mRNA vaccine production in Africa

Fierce Pharma

As various efforts to produce next-generation vaccines in Africa are being carried forward by the likes of the World Health Organization (WHO) and the Bill & Melinda Gates Foundation, BioNTech | Under an expansion of the partners’ existing deal, the Coalition for Epidemic Preparedness Innovations (CEPI) is committing up to $145 million to bolster BioNTech’s efforts to establish vaccine R&D and manufacturing capabilities at the German company’s facility in Kigali, Rwanda.

More Trending

article thumbnail

As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’

PharmaVoice

To lower drug prices, lawmakers are turning to the drug patent system to outlaw some common practices — but a former patent agency director says it’s the wrong way to go.

111
111
article thumbnail

How to Become A Medical Device Sales Rep in 2024?

David Bagga

Medical device sales is a burgeoning market, with jobs that have an extremely high earning potential. In 2018, the average base salary of a medical sales representative was $92,698 How to Become A Medical Device Sales Rep in 2024? Home Blog How to Become A Medical Device Sales Rep in 2024? How to Become A […] The post How to Become A Medical Device Sales Rep in 2024?

Medical 130
article thumbnail

CSL Seqirus scores 4th award from US government for bird flu pandemic preparedness

Fierce Pharma

The United States Department of Health and Human Services has expanded its avian flu pandemic preparedness partnership with CSL Seqirus, lining up the vaccine specialist to

article thumbnail

With M&A Deal, Click Therapeutics’ Digital Prospects in Metabolic Disease Get Better

MedCity News

Click Therapeutics is acquiring the assets of Better Therapeutics two months after that digital therapeutics developer announced it would lay off all employees and shut down. Better’s main asset is AspyreRx, an FDA-authorized mobile app for type 2 diabetes. The post With M&A Deal, Click Therapeutics’ Digital Prospects in Metabolic Disease Get Better appeared first on MedCity News.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Can robots break the cell therapy bottleneck?

PharmaVoice

A partnership between the cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could bring the manufacturing bottleneck under control, the CEOs said.

article thumbnail

How to Become A Medical Sales Rep With No Experience 2024?

David Bagga

Medical device sales is a burgeoning market, with jobs that have an extremely high earning potential. In 2018, the average base salary of a medical sales representative was $92,698 How to Become A Medical Sales Rep With No Experience 2024? Home Blog How to Become A Medical Sales Rep With No Experience 2024? How to […] The post How to Become A Medical Sales Rep With No Experience 2024?

article thumbnail

ASCO: In surprise, J&J's injectable Rybrevant extends lung cancer patients' lives versus intravenous version

Fierce Pharma

When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. | When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. But to Johnson & Johnson’s surprise, a subcutaneous formulation of its lung cancer med Rybrevant proved to work better than the original infusion.

Patients 317
article thumbnail

Protect Personalized, Independent Kidney Care

MedCity News

A pending CMS policy could cause havoc for independent kidney care facilities and patients who need life-sustaining treatments. The post Protect Personalized, Independent Kidney Care appeared first on MedCity News.

Patients 111
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

pharmaphorum

The overall survival (OS) data has come in from the TROPION-Lung01 study of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in lung cancer – and the result likely isn’t what they were hoping for.

111
111
article thumbnail

How Much Do Medical Device Sales Reps Make in 2024?

David Bagga

How Much Do Medical Device Sales Reps Make in 2024? Home Blog How Much Do Medical Device Sales Reps Make in 2024? How Much Do Medical Device Sales Reps Make in 2024? When looking for a medical device sales rep job, a common question is, ‘How much does a medical device sales rep earn? It’s […] The post How Much Do Medical Device Sales Reps Make in 2024?

Medical 130
article thumbnail

Data breach at pharma partner Cencora puts sensitive patient information at risk

Fierce Pharma

A data breach at drug distributor Cencora has left sensitive information vulnerable, with patients on medicines from a dozen drugmakers potentially affected. | The potentially compromised data included patient information such as names and addresses, Cencora disclosed in letters to patients who may have been affected.

Patients 324
article thumbnail

Plenful Raises $17M to Help Curb Rising Levels of Pharmacy Burnout

MedCity News

Plenful has completed a $17 million Series A funding round, bringing its total fundraising amount to date to more than $25 million. The startup offers a software platform that automates the manual and administrative tasks that burden pharmacists and pharmacy technicians. The post Plenful Raises $17M to Help Curb Rising Levels of Pharmacy Burnout appeared first on MedCity News.

107
107
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

US Congress passes bill to end Parkinson’s disease

pharmaphorum

The US Congress has passed the first-ever federal bill dedicated to ending Parkinson’s disease, modelled on similar legislation for Alzheimer’s enacted in 2011

110
110
article thumbnail

FDA Enforcement Discretion: A Strategic Path to Market for Digital Health and Digital Therapeutics Companies

Nixon Gwilt Law

Healthcare delivery is changing, and digital health is revolutionizing healthcare, creating a burgeoning market opportunity for software-as-a-medical-device (SaMD) and digital therapeutic (DTx) products. These innovations can improve patient outcomes while creating revenue potential through direct-to-consumer sales, contracts with health plans, and existing billing codes like the remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) code sets.

article thumbnail

Gilead's Trodelvy suffers double whammy as failed bladder cancer trial raises flag over early deaths

Fierce Pharma

In the span of half a year, Gilead Sciences' Trodelvy has flopped a second phase 3 trial. | Following a high-profile lung cancer setback in January, Gilead said Thursday that Trodelvy also failed to move the needle in a bladder cancer study. The flop threatens the ADC's accelerated approval in the tumor type.

317
317
article thumbnail

Making Access to AI-enabled Medical Devices Equitable for All

MedCity News

If Medicare acts, the potential of AI-enabled technologies to improve healthcare outcomes for patients, regardless of their geographic location or socioeconomic status, will be closer to being fully realized. The post Making Access to AI-enabled Medical Devices Equitable for All appeared first on MedCity News.

Medical 110
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Novartis cues up filings for remibrutinib in chronic hives

pharmaphorum

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long-term data from two phase 3 trials.

100
100
article thumbnail

Improving stem cell transplantation success in high-risk blood cancers

European Pharmaceutical Review

Repurposing cyclophosphamide may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, new research suggests. These new findings, which are part of an ongoing Phase II study , will be presented at the 2024 American Society of Clinical Oncology (ASCO) meeting and the European Hematology Association ( Abstract #6503 ).

article thumbnail

Bristol Myers secures another FDA go-ahead for Breyanzi, this time in mantle cell lymphoma

Fierce Pharma

In the years since gaining an initial FDA approval for Breyanzi, Bristol Myers Squibb has worked hard to expand the reach of its cell therapy. | In the years since gaining an initial FDA approval for Breyanzi, Bristol Myers Squibb has worked hard to expand the reach of its cell therapy. For the third time in as many months, those efforts have yielded a label expansion at the FDA.

FDA 308
article thumbnail

The Top 3 Reasons That Hospitals’ Tech Pilots Fail

MedCity News

Justin Brueck, vice president of innovation and research at Endeavor Health, shared three main reasons that technology pilots end up being unsuccessful at health systems. The post The Top 3 Reasons That Hospitals’ Tech Pilots Fail appeared first on MedCity News.

111
111
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Working for a mature form of genomic medicines

pharmaphorum

In a new episode of the pharmaphorum podcast, Rahul Kakkar, CEO of gene editing company Tome, speaks with web editor Nicole Raleigh about programmable genomic integration (PGI) technology.

Medicine 101
article thumbnail

FDA grants RMAT status for BlueRock’s Parkinson’s therapy

Pharmaceutical Technology

The US FDA has granted RMAT designation for BlueRock Therapeutics' cell therapy, bemdaneprocel (BRT-DA01), for Parkinson's disease.

FDA 105
article thumbnail

Verona's ensifentrine will be a 'paradigm shift in COPD treatment,' GlobalData says

Fierce Pharma

With a target date for FDA approval less than a month away, Sanofi and Regeneron’s megablockbuster Dupixent has gained much attention as it is on the verge of becoming the first biologic to treat c | With Verona Pharmaceuticals' COPD candidate ensifentrine approaching its FDA decision date, GlobalData has referred to it as a “paradigm shift in COPD treatment.

FDA 306
article thumbnail

FDA Approves Moderna RSV Vaccine, an mRNA Alternative to GSK and Pfizer Products

MedCity News

Moderna’s mResvia is now the third FDA-approved RSV vaccine and the first one based on mRNA technology. It will compete for market share against RSV shots from GSK and Pfizer that won their FDA nods last year. The post FDA Approves Moderna RSV Vaccine, an mRNA Alternative to GSK and Pfizer Products appeared first on MedCity News.

FDA 103
article thumbnail

ABM Evolution: How Top Marketers Are Using Account-Based Strategies

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.